Switch to:
Also traded in: Germany, Israel

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 17.03
BTX's Cash-to-Debt is ranked lower than
55% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: 59.90 vs. BTX: 17.03 )
Ranked among companies with meaningful Cash-to-Debt only.
BTX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.01  Med: No Debt Max: No Debt
Current: 17.03
Equity-to-Asset 0.81
BTX's Equity-to-Asset is ranked higher than
69% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. BTX: 0.81 )
Ranked among companies with meaningful Equity-to-Asset only.
BTX' s Equity-to-Asset Range Over the Past 10 Years
Min: -45.87  Med: 0.33 Max: 0.99
Current: 0.81
-45.87
0.99
Piotroski F-Score: 4
Altman Z-Score: 5.69
Beneish M-Score: -2.85
WACC vs ROIC
18.57%
-124.88%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -1102.02
BTX's Operating Margin % is ranked lower than
77% of the 743 Companies
in the Global Biotechnology industry.

( Industry Median: -88.13 vs. BTX: -1102.02 )
Ranked among companies with meaningful Operating Margin % only.
BTX' s Operating Margin % Range Over the Past 10 Years
Min: -1262.65  Med: -343.57 Max: -116.83
Current: -1102.02
-1262.65
-116.83
Net Margin % 400.25
BTX's Net Margin % is ranked higher than
99% of the 743 Companies
in the Global Biotechnology industry.

( Industry Median: -75.28 vs. BTX: 400.25 )
Ranked among companies with meaningful Net Margin % only.
BTX' s Net Margin % Range Over the Past 10 Years
Min: -989.69  Med: -337.07 Max: 400.25
Current: 400.25
-989.69
400.25
ROE % 49.26
BTX's ROE % is ranked higher than
97% of the 874 Companies
in the Global Biotechnology industry.

( Industry Median: -34.32 vs. BTX: 49.26 )
Ranked among companies with meaningful ROE % only.
BTX' s ROE % Range Over the Past 10 Years
Min: -381.18  Med: -142.42 Max: 49.26
Current: 49.26
-381.18
49.26
ROA % 25.04
BTX's ROA % is ranked higher than
97% of the 972 Companies
in the Global Biotechnology industry.

( Industry Median: -30.23 vs. BTX: 25.04 )
Ranked among companies with meaningful ROA % only.
BTX' s ROA % Range Over the Past 10 Years
Min: -624.96  Med: -63.91 Max: 25.04
Current: 25.04
-624.96
25.04
ROC (Joel Greenblatt) % -1083.27
BTX's ROC (Joel Greenblatt) % is ranked lower than
63% of the 925 Companies
in the Global Biotechnology industry.

( Industry Median: -407.53 vs. BTX: -1083.27 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
BTX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -20611.76  Med: -2458 Max: -1083.27
Current: -1083.27
-20611.76
-1083.27
3-Year Revenue Growth Rate 3.20
BTX's 3-Year Revenue Growth Rate is ranked lower than
51% of the 480 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. BTX: 3.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
BTX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -51.6  Med: 8 Max: 100.7
Current: 3.2
-51.6
100.7
3-Year EBITDA Growth Rate 18.40
BTX's 3-Year EBITDA Growth Rate is ranked higher than
69% of the 521 Companies
in the Global Biotechnology industry.

( Industry Median: 1.70 vs. BTX: 18.40 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
BTX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -48.5  Med: 8 Max: 70.2
Current: 18.4
-48.5
70.2
3-Year EPS without NRI Growth Rate 10.30
BTX's 3-Year EPS without NRI Growth Rate is ranked higher than
66% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: -3.10 vs. BTX: 10.30 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
BTX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -35.2  Med: 10.1 Max: 67.1
Current: 10.3
-35.2
67.1
GuruFocus has detected 2 Warning Signs with BioTime Inc $BTX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» BTX's 10-Y Financials

Financials (Next Earnings Date: 2017-03-16)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

BTX Guru Trades in

BTX Guru Trades in

Q2 2015

BTX Guru Trades in Q2 2015

Jim Simons 165,000 sh (New)
» More
Q3 2015

BTX Guru Trades in Q3 2015

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with BTX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2836
Compare:NAS:VYGR, OTCPK:PTCHF, NAS:CCXI, NAS:OMED, NAS:SVA, NAS:NERV, NAS:LJPC, NAS:ARNA, NAS:GERN, NAS:BOLD, NAS:PRTK, NAS:EDGE, NAS:ADXS, OTCPK:RCAR, NAS:BLCM, NAS:ADAP, NAS:BSTC, NAS:FOMX, NAS:PDLI, NAS:CRIS » details
Traded in other countries:BT3.Germany, BTX.Israel,
BioTime Inc is a biotechnology company. The Company is engaged in the biomedical research and product development in regenerative medicine including human embryonic stem cell and induced pluripotent stem cell technology.

BioTime Inc was incorporated in 1990 in the state of California. It is a biotechnology company engaged in two areas of biomedical research and product development. Its main focus is in the field of regenerative medicine; specifically human embryonic stem (hES) cell and induced pluripotent stem (iPS) cell technology. Regenerative medicine refers to therapies based on stem cell technology that are designed to rebuild cell and tissue function lost due to degenerative disease or injury. hES and iPS cells provide a means of manufacturing every cell type in the human body and therefore show considerable promise for the development of a number of new therapeutic products. Its core technologies center on stem cells capable of becoming all of the cell types in the human body, a property called pluripotency. Products made from these pluripotent stem cells are being developed by the Company and its subsidiaries, for use in various fields of medicine, including: neuroscience, oncology, orthopedics, and blood and vascular diseases. HyStem, Hextend, ESpy, PureStem, and PentaLyte are registered trademarks of the Company and Renevia, Premvia, ReGlyde, and ESpan are trademarks of the Company.

Ratios

vs
industry
vs
history
PE Ratio 15.71
BTX's PE Ratio is ranked higher than
78% of the 277 Companies
in the Global Biotechnology industry.

( Industry Median: 27.60 vs. BTX: 15.71 )
Ranked among companies with meaningful PE Ratio only.
BTX' s PE Ratio Range Over the Past 10 Years
Min: 13.57  Med: 16.48 Max: 18.57
Current: 15.71
13.57
18.57
PE Ratio without NRI 15.71
BTX's PE Ratio without NRI is ranked higher than
78% of the 251 Companies
in the Global Biotechnology industry.

( Industry Median: 27.87 vs. BTX: 15.71 )
Ranked among companies with meaningful PE Ratio without NRI only.
BTX' s PE Ratio without NRI Range Over the Past 10 Years
Min: 13.57  Med: 16.48 Max: 18.57
Current: 15.71
13.57
18.57
Price-to-Owner-Earnings 11.50
BTX's Price-to-Owner-Earnings is ranked higher than
80% of the 143 Companies
in the Global Biotechnology industry.

( Industry Median: 29.18 vs. BTX: 11.50 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
BTX' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 9.93  Med: 12.06 Max: 13.59
Current: 11.5
9.93
13.59
PB Ratio 2.82
BTX's PB Ratio is ranked higher than
64% of the 1106 Companies
in the Global Biotechnology industry.

( Industry Median: 3.65 vs. BTX: 2.82 )
Ranked among companies with meaningful PB Ratio only.
BTX' s PB Ratio Range Over the Past 10 Years
Min: 2.45  Med: 10.12 Max: 45.12
Current: 2.82
2.45
45.12
PS Ratio 48.56
BTX's PS Ratio is ranked lower than
72% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: 12.50 vs. BTX: 48.56 )
Ranked among companies with meaningful PS Ratio only.
BTX' s PS Ratio Range Over the Past 10 Years
Min: 4.29  Med: 39.89 Max: 106.11
Current: 48.56
4.29
106.11
PEG Ratio 0.50
BTX's PEG Ratio is ranked higher than
88% of the 98 Companies
in the Global Biotechnology industry.

( Industry Median: 2.11 vs. BTX: 0.50 )
Ranked among companies with meaningful PEG Ratio only.
BTX' s PEG Ratio Range Over the Past 10 Years
Min: 0  Med: 0 Max: N/A
Current: 0.5
Current Ratio 4.22
BTX's Current Ratio is ranked higher than
51% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. BTX: 4.22 )
Ranked among companies with meaningful Current Ratio only.
BTX' s Current Ratio Range Over the Past 10 Years
Min: 0.02  Med: 4 Max: 76
Current: 4.22
0.02
76
Quick Ratio 4.22
BTX's Quick Ratio is ranked higher than
53% of the 948 Companies
in the Global Biotechnology industry.

( Industry Median: 3.91 vs. BTX: 4.22 )
Ranked among companies with meaningful Quick Ratio only.
BTX' s Quick Ratio Range Over the Past 10 Years
Min: 0.02  Med: 3.99 Max: 74
Current: 4.22
0.02
74
Days Inventory 77.15
BTX's Days Inventory is ranked higher than
69% of the 439 Companies
in the Global Biotechnology industry.

( Industry Median: 126.28 vs. BTX: 77.15 )
Ranked among companies with meaningful Days Inventory only.
BTX' s Days Inventory Range Over the Past 10 Years
Min: 44.02  Med: 75.44 Max: 540.98
Current: 77.15
44.02
540.98
Days Sales Outstanding 99.61
BTX's Days Sales Outstanding is ranked lower than
71% of the 592 Companies
in the Global Biotechnology industry.

( Industry Median: 62.87 vs. BTX: 99.61 )
Ranked among companies with meaningful Days Sales Outstanding only.
BTX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 85.34  Med: 91.79 Max: 99.61
Current: 99.61
85.34
99.61
Days Payable 1.00
BTX's Days Payable is ranked lower than
96% of the 396 Companies
in the Global Biotechnology industry.

( Industry Median: 57.94 vs. BTX: 1.00 )
Ranked among companies with meaningful Days Payable only.
BTX' s Days Payable Range Over the Past 10 Years
Min: 1  Med: 1001.68 Max: 5165.44
Current: 1
1
5165.44

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -22.30
BTX's 3-Year Average Share Buyback Ratio is ranked lower than
69% of the 556 Companies
in the Global Biotechnology industry.

( Industry Median: -10.90 vs. BTX: -22.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BTX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -27.3  Med: -13.6 Max: -2.1
Current: -22.3
-27.3
-2.1

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 110.00
BTX's Price-to-Net-Cash is ranked lower than
97% of the 749 Companies
in the Global Biotechnology industry.

( Industry Median: 5.89 vs. BTX: 110.00 )
Ranked among companies with meaningful Price-to-Net-Cash only.
BTX' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 10.21  Med: 26.36 Max: 369
Current: 110
10.21
369
Price-to-Net-Current-Asset-Value 47.14
BTX's Price-to-Net-Current-Asset-Value is ranked lower than
94% of the 879 Companies
in the Global Biotechnology industry.

( Industry Median: 5.57 vs. BTX: 47.14 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
BTX' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 9.76  Med: 22.02 Max: 147.6
Current: 47.14
9.76
147.6
Price-to-Tangible-Book 3.11
BTX's Price-to-Tangible-Book is ranked higher than
68% of the 1015 Companies
in the Global Biotechnology industry.

( Industry Median: 4.36 vs. BTX: 3.11 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
BTX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.8  Med: 20.61 Max: 137.1
Current: 3.11
2.8
137.1
Price-to-Median-PS-Value 1.22
BTX's Price-to-Median-PS-Value is ranked lower than
60% of the 765 Companies
in the Global Biotechnology industry.

( Industry Median: 0.97 vs. BTX: 1.22 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
BTX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.11  Med: 1.16 Max: 27.17
Current: 1.22
0.11
27.17
Price-to-Graham-Number 1.48
BTX's Price-to-Graham-Number is ranked higher than
72% of the 229 Companies
in the Global Biotechnology industry.

( Industry Median: 2.38 vs. BTX: 1.48 )
Ranked among companies with meaningful Price-to-Graham-Number only.
BTX' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.33  Med: 1.75 Max: 1.75
Current: 1.48
1.33
1.75
Earnings Yield (Greenblatt) % -21.16
BTX's Earnings Yield (Greenblatt) % is ranked lower than
73% of the 1203 Companies
in the Global Biotechnology industry.

( Industry Median: -9.03 vs. BTX: -21.16 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
BTX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -31.84  Med: 0 Max: 0
Current: -21.16
-31.84
0

More Statistics

Revenue (TTM) (Mil) $6.30
EPS (TTM) $ 0.21
Beta2.14
Short Percentage of Float7.83%
52-Week Range $2.21 - 4.01
Shares Outstanding (Mil)111.20

Analyst Estimate

Dec16 Dec17
Revenue (Mil $) 6 6
EPS ($) 0.19 -0.46
EPS without NRI ($) 0.19 -0.46
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for BTX

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight: BTX, CWST, BKSC, STAG Jun 27 2011 
Weekly CEO Buys Highlight: PCYC, HLX, FSC, CREG, BTX Jun 25 2011 

More From Other Websites
BioTime, Inc. breached its 50 day moving average in a Bullish Manner : BTX-US : February 24, 2017 Feb 24 2017
BioTime, Inc. to Announce Fourth Quarter and Fiscal 2016 Results on March 16, 2017 Feb 23 2017
BioTime Reports $56M Non-Cash Gain On Deconsolidation Feb 22 2017
BioTime (BTX) Shows Strength: Stock Adds 7.1% in Session Feb 22 2017
BioTime Reports Pro Forma Gain on Deconsolidation of OncoCyte Subsidiary Feb 21 2017
BIOTIME INC Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Financial... Feb 21 2017
BIOTIME INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Feb 15 2017
BioTime, Inc. Announces Closing of Public Offering of Common Stock Feb 15 2017
CORRECTING and REPLACING BioTime Expands Ophthalmology Portfolio With Global In-Licensing Agreement... Feb 15 2017
BioTime to Present at Two Upcoming Investor Conferences Feb 13 2017
BIOTIME INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and... Feb 13 2017
BioTime Declares $17.5M Public Stock Offering Feb 10 2017
BioTime, Inc. Announces Pricing of Public Offering of Common Stock Feb 10 2017
BIOTIME INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Feb 09 2017
BioTime, Inc. Announces Proposed Public Offering of Common Stock Feb 09 2017
Acorda, Amgen and Regeneron Lead Premarket Biotech Movers Feb 09 2017
BioTime Appoints Industry Veteran, Stephana Patton, Ph.D., J.D., as General Counsel Feb 07 2017
BioTime Expands Ophthalmology Portfolio With Global In-Licensing Agreement for Next-Generation... Feb 06 2017
LifeSci Capital Initiates Coverage of BioTime, Inc. Jan 30 2017
BioTime to Present at Noble Capital Markets’ Thirteenth Annual Investor Conference Jan 26 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)